<DOC>
	<DOCNO>NCT00187161</DOCNO>
	<brief_summary>This pilot study demonstrate modify LMB-89 treatment regimen child newly diagnose small noncleaved cell NHL , large cell NHL ( B-cell ) , B-cell acute lymphoblastic leukemia deliver set acceptable toxicity .</brief_summary>
	<brief_title>Treatment Burkitt Lymphoma/Leukemia B Large Cell NHL</brief_title>
	<detailed_description>Group A : Resected Stage I resect abdominal Stage II Subjects receive two course ( 3 week apart ) COPAD follow : Cyclophosphamide ( CTX ) 500 mg/m2/day ( divide q12 hr ) IV day 1 , 2 , 3 Vincristine ( VCR ) 2 mg/m2 ( max 2.0 mg ) IV day 1 , 6 Prednisone 60 mg/m2/d ( divide bid ) PO day 1-5 Adriamycin 60 mg/m2 6 hr IV day 1 GCSF 5 mcg/kg/day SQ give day start day 7 blood count recover . Group B : Other Stage II , Stage III , Stage IV B-ALL M blast &lt; 70 % ; CNS involvement . Treatment Pre-Induction Subjects Group B receive one week treatment COP follow : CTX 300 mg/m2 IV day 1 ; VCR 1 mg/m2 ( max 2.0 mg ) IV day 1 ; Prednisone 60 mg/m2/day ( divide bid ) PO day 1-7 ; Methotrexate ( MTX ) hydrocortisone ( HC ) spinal fluid ( IT ) , age adjust , day 1 ; Induction -COPADM x 2 ( COPAD M3 # 1 ( start day 8 COP great equal 20 % reduction tumor size day 7 COP ; &lt; 20 % proceed Group C start COPADM8 No . 1 ) ; COPADM3 # 1 VCR 2 mg/m2 ( max 2 mg ) IV day 1 ; High-dose ( HD ) MTX 3 gm/m2 IV ( 3 hr ) day 1 ; MTX HC age adjust IT day 2 , 6 CTX 500 mg/m2/day ( divide q12 hr ) IV day 2 , 3 , 4 ; Adriamycin 60 mg/m2 6 hr IV ; day 2 ; Prednisone 60 mg/m2 ( divide bid ) po day 1-5 . G-CSF 5 mcg/kg/day start day 7 count recover . COPADM3 # 2 Like COPADM # 1 ( ) except : 1 . CTX - double dose ( 1 gm/m2/day ) ( divide q12 hr ) 2 . VCR - second dose give day 6 Consolidation- CYM x 2 course HDMTX 3 gm/m2 ( 3 hr ) IV Day 1 ; MTX plus HC age adjust IT day 2 ; Cytarabine ( Ara-C ) 100 mg/m2/day CI/IV ( x 5 day ) day 2-6 ; Ara-C HC age adjust IT day 7 . Maintenance Sequence 1 Prednisone 60 mg/m2/d ( divide bid ) PO day 1-5 ; HDMTX 3 gm/m2 ( 3 hr ) IV Day 1 ; MTX plus HC age adjust IT day 2 ; CTX 500 mg/m2/day IV day 2 , 3 ; Adriamycin 60 mg/m2 ( 6 hr ) IV day 3 ; VCR 2 mg/m2 ( max 2 mg ) IV day 1 . G-CSF 5 mcg/kg/day start day 6 count recover . Group C : B-ALL &gt; 70 % BM blast ; CNS involvement , Group B COP failures i.e. , &lt; 20 % reduction Treatment Pre-Induction Subjects receive one week treatment COP follow : CTX 300 mg/m2 IV day 1 VCR 1 mg/m2 ( max 2 mg ) IV day 1 Prednisone 60 mg/m2/d ( divide ) bid po day 1-7 MTX + HC + Ara-C age adjust IT day 1 , 3 , 5 Leucovorin 15 mg/m2 q12 hr x 2 po day 2 , 4 Induction-COPADM x 2 Subjects begin induction therapy day COP finish follow : COPADM8 # 1 VCR 2 mg/m2 ( max 2 mg ) IV day 1 ; HD MTX 8 gm/m2 ( 4 hr ) IV Day 1 ; MTX+HC+Ara-C age adjust IT day 1 , 4 , 6 ( Ommaya , day 1 ) ; CTX 500 mg/m2/day divide every 12 hour IV day 2 , 3 , 4 ; Adriamycin 60 mg/m2 ( 6 hr ) IV day 2 ; Prednisone 60 mg/m2/day ( divide bid ) po/IV day 1-5 . G-CSF 5 mcg/kg/day start day 7 count recover . COPADM8 # 2 Like COPAD M8 # 1 except : 1 . CTX-double dose ( 1 gm/m2/day ) ( divide q12hs ) IV 2 . VCR - 2nd dose give day 6 Consolidation - CYVE x 2 course Ara-C 50 mg/m2/12 hr CI/IV Day 1-5 ; HD Ara-C 3 gm/m2/day IV 3 hour Day 2-5 ; VP-16 200 mg/m2/day IV 2 hour Day 2-5 . Maintenance : Subjects receive four course chemotherapy continuation . Each course use different chemotherapy drug . Sequence 1 Prednisone 60 mg/m2/day ( divide bid ) po/IV day 1-5 ; HD MTX 8 gm/m2 ( 4 hr ) IV Day 1 ; MTX+HC+Ara-C age adjust IT day 2 ( Ommaya , day 2 ) CTX 500 mg/m2 IV day 2 , 3 ; Adriamycin 60 mg/m2 ( 6 hr ) IV day 3 ; VCR 2 mg/m2 ( max 2 mg ) IV day 1 . G-CSF 5 mcg/kg/day start day 7 count recover . Sequence 2 Ara-C 100 mg/m2/day ( divide q12 hr ) SQ Day 1-5 ; VP-16 150 mg/m2/day ( 2 hr ) IV Days 1-3 ; G-CSF 5 micro g/kg SQ Days 6 count recovery ; MTX+HC+Ara-C age adjust IT Day 1 ( CNS positive , ) Ommaya Day 1 ( CNS positive , ) Sequence 3 Prednisone 60 mg/m2/day ( divide bid ) po day 1-5 ; CTX 500 mg/m2/day IV day 1 , 2 ; Adriamycin 60 mg/m2 ( 6 hr ) IV day 2 ; VCR 2 mg/m2 ( max 2 mg ) IV day 1 ; G-CSF 5 mcg/kg SQ start day 6 count recover ; MTX+HC+Ara-C age adjust IT Day 1 ( CNS positive , ) Ommaya Day 1 ( CNS positive , ) . Sequence 4 Ara-C 100 mg/m2/day ( divide q12 hr ) SQ Day 1-5 ; VP-16 150 mg/m2/day ( 2 hr ) IV Days 1-3 ; G-CSF 5 mcg/kg SQ day 6 count recover ; MTX+HC+Ara-C age adjust IT Day 1 ( CNS positive , ) Ommaya Day 1 ( CNS positive , ) Intrathecal ( IT ) Treatment dose volume follow : &lt; 1 year , MTX 8 mg , HC 8 mg , Ara C 15 mg , Volume 8 ml ; Age 12-23 mo , MTX 10 mg , HC 10 mg , Ara C 20 mg , Volume 10 ml ; Age 24-35 mo , MTX 12 mg , HC 12 mg , Ara C 25 mg , Volume 12 ml ; Age ≥3 yr , MTX 15 mg , HC 15 mg , Ara C 30 mg. Volume 15 ml Ommaya Reservoir Treatment ( CNS positive ) Age ≥3 yr , MTX 6 mg , HC 15 mg , Ara C 50 mg/m2 ( 50 mg max ) Volume 3 ml</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Subject must previously untreated , except steroid . Subject must less equal 18 year age . Subject must histologic diagnosis small noncleaved cell ( SNCC ) NHL large cell NHL ( Bcell ) , Bcell acute lymphocytic leukemia . Previously treat disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Mature B-Cell Leukemia</keyword>
	<keyword>Non-Hodgkin Lymphoma</keyword>
	<keyword>Burkitt 's lymphoma</keyword>
	<keyword>Small noncleaved cell non Hodgkin lymphoma</keyword>
	<keyword>Large cell lymphoma</keyword>
</DOC>